Cytori Therapeutics, Inc.
) provided preliminary data from a study evaluating a potential
treatment for scleroderma based on the company's cell therapy.
The investigator-funded, open-label, pilot study is being
conducted on patients with cutaneous systemic scleroderma in
12 patients were administered Cytori's cell therapy, injected
into their fingers. Safety and hand function improvement are the
primary endpoints of the study which were measured by the Cochin
hand functional scale at six months.
At the end of the two month follow-up period, no infection,
ischemic complications or serious adverse events were observed.
Moreover, there was a significant improvement in the Cochin hand
function disability scale.
As far as secondary endpoints are concerned, there was a
significant improvement in scleroderma health assessment
questionnaire score and in Raynaud's Severity Score. Also, there
was a significant improvement in hand pain when measured by the
visual analog pain scale.
Cytori is focused primarily on the development of treatments
for cardiovascular disease and soft tissue injuries and burns
based on its proprietary cell therapy formulation. The company's
cell therapy is based on the formulation of stem and regenerative
cells derived from a patient's own adipose (fat) tissue (ADRCs).
The company has also designed the Celution System, a tissue
processing system, to access the cells from a patient during the
We note that last month Cytori's Celution System gained
approval from the Australian regulatory body for commercial use
for autologous re-implantation or re-infusion of a patient's
The company is currently conducting Athena, a multi-center,
double-blind, randomized and placebo-controlled study for
evaluating its cell therapy in 45 patients with chronic ischemic
heart failure. The company expects to complete patient enrollment
in the fourth quarter of this year. 6-month top-line data from
the study is expected in the first half of next year.
Cytori carries a Zacks Rank #4 (Sell). Companies that
currently look well-positioned include
Gilead Sciences Inc.
) with a Zacks Rank #1 (Strong Buy), and
) with a Zacks Rank #2 (Buy).
ACTELION LTD (ALIOF): Get Free Report
CYTORI THERAPEU (CYTX): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
To read this article on Zacks.com click here.